SCHEMBL6987564

SCHEMBL6987564

N#CCCc1cc2c(cc1Br)OCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
DPP4 P27487 1/20 0.38
KCNH2 Q12809 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
HSP90AA1 P07900 7/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 3/20 0.35
GAA P10253 1/20 0.35
HSP90B1 P14625 4/20 0.34
TRAP1 Q12931 4/20 0.34
HPGD P15428 1/20 0.34
ERBB2 P04626 1/20 0.33
HSP90AB1 P08238 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6239124 0.82 CYP3A4 (0.41) CYP3A4CYP1A2CYP2D6CYP2C19POLB
SCHEMBL3533639 0.81 CYP3A4 (0.40) CYP3A4CYP1A2CYP2D6CYP2C19POLB
SCHEMBL25907658 0.76 TAAR1 (0.52) CYP3A4CYP1A2CYP2D6CYP2C19POLB
SCHEMBL17980277 0.76 CYP3A4 (0.48) CYP3A4CYP1A2CYP2D6CYP2C19POLB
SCHEMBL30360689 0.76 CYP3A4 (0.48) CYP3A4CYP1A2CYP2D6CYP2C19POLB
SCHEMBL28346620 0.73 TAAR1 (0.44) CYP3A4CYP1A2CYP2D6CYP2C19POLB
SCHEMBL1520657 0.72 CYP3A4 (0.44) CYP3A4CYP1A2CYP2D6CYP2C19MEN1
SCHEMBL15701378 0.72 HTT (0.37) MEN1KMT2ATSHR
SCHEMBL8249225 0.71 TAAR1 (0.61) CYP3A4CYP1A2CYP2D6CYP2C19MEN1
SCHEMBL6239134 0.71 CYP1A2 (0.44) CYP3A4CYP1A2CYP2D6CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1146041-B1 Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline SERVIER LAB (FR) 2003-11-12 EP disclosed
US-6420413-B2 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA LES LABORATORIES SERVIER (FR) 2002-07-16 US disclosed
US-20020019380-A1 Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds LES LABORATOIRES SERVIER (FR) 2002-02-14 US disclosed
EP-1146041-A1 Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline ADIR ET COMPAGNIE (FR) 2001-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019380-A1 Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds HSD3B2, HSD3B1, NR1H3 CYP3A4 307/4885CYP1A2 208/4885CYP2D6 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.